We analyzed online datasets in Oncomine, TIMER, and some other database comprehensively to identify potential biomarkers for prognosis and immune infiltration in tumor patients, and found that TIMP1 associates not only with prognosis of GBM but also with the levels of immune infiltration seen in those patients. This evidence concerns the gene TIMP1 and neoplasm.